B-I's all oral, interferon-free combo regimen meets PhIIb goals in HCV genotype-1 patients
This article was originally published in Scrip
Boehringer Ingelheim said that its interferon-free therapy – combining the company’s investigational direct-acting antiviral compounds - met the goals in treating HCV in genotype-1 patients after a pre-specified interim analysis of the ongoing, 362-patient Phase IIb SOUND-C2 trial. Most significantly, a subgroup of this hard-to-treat population, those with two prevalent types of HCV found across Europe and Asia (genotype-1a CC and -1b), had viral cure rates (SVR12) without interferon in up to 82% of patients after just 28 weeks of treatment.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.